Eastland Medical Systems LTD

ASX Release

EASTLAND's PHASE III CLINICAL TRIAL UPDATE PATIENT FOLLOW-UP COMPLETED FIELD TRIAL NOW COMPLETE

Eastland's Board is pleased to provide you with the following update from the African ART004 Clinical Trial titled,

"A Phase III, randomized, open labelled, active controlled, multi-centre, superiority trial of ArTiMist™ versus intravenous quinine in children with severe or complicated falciparum malaria, or uncomplicated falciparum malaria with gastrointestinal complications."

We have received confirmation that the recruitment of patients for the trial is complete and the trial is now fully enrolled. We can also confirm that patient dosing has also been completed and that all patients have now completed their 28 day follow-up. This marks the completion of the field aspects of the clinical trial. This is a significant milestone in the development program for ArTiMist™.

The pharmacodynamics studies, biochemistry and parasitology and other evaluations of the patient data are now underway. These results will then be forwarded to the Biostatisticians for analysis and then to the Medical Writer for compilation into the final clinical report. It is anticipated that this should be completed during the 4th quarter of this year.

Not wanting to foreshadow the statistical scientific evidence of the trial results, Management remains confident that these confirmatory trials will support the conclusions of the Phase II trials that ArTiMist™ can provide a viable alternative to the commonly accepted treatment of intravenous quinine.

Eastland's Board will provide a further update on the progress of the manufacturing program in the near future.

Further information:
Stephen Carter
Chief Executive Officer
Director
Eastland Medical Systems Ltd
Tel: +61 8 6142 5555
sjcarter@eastlandmedical.com.au

BACKGROUND

Over 1 million children die every year from malaria. The majority of deaths from severe malaria in childhood are caused by the delayed administration of effective antimalarial treatment. There is a relentless deterioration in the clinical condition of a young child with malaria who fails to get effective treatment, with death ensuing in a matter of hours or days. Any successful attempt to reduce mortality from malaria will have to explore novel possibilities for minimising such delays.

ArTiMist™ treatment is administered sub-lingually or under the tongue and enters the bloodstream where the parasite lives, attacking at a far greater speed than conventional tablets and reducing the need for continued hospitalisation whilst presenting significant potential cost savings to governments and relief organisations. ArTiMist™ is especially effective in the treatment of children and young infants who are experiencing malaria-related and gastro-intestinal problems and cannot tolerate tablet treatments.

- ArTiMist™ addresses major global un-met medical need in the treatment of children with severe malaria.
- 2 patent families, granted in some countries and undergoing examination via PCT in others.
- Progressing rapidly to commercialisation of world's first sub-lingual malaria treatment for children
- ArTiMist™ was identified by Thompson Reuters as one of the 5 most promising drugs in Phase III clinical development.